125 related articles for article (PubMed ID: 17804466)
1. Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
Försti A; Lei H; Tavelin B; Enquist K; Palmqvist R; Altieri A; Hallmans G; Hemminki K; Lenner P
Ann Oncol; 2007 Dec; 18(12):1990-4. PubMed ID: 17804466
[TBL] [Abstract][Full Text] [Related]
2. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
Lei H; Hemminki K; Johansson R; Altieri A; Enquist K; Henriksson R; Lenner P; Försti A
Breast Cancer Res Treat; 2008 May; 109(1):165-75. PubMed ID: 17616807
[TBL] [Abstract][Full Text] [Related]
3. Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness.
Buø L; Meling GI; Karlsrud TS; Johansen HT; Aasen AO
Hum Pathol; 1995 Oct; 26(10):1133-8. PubMed ID: 7557947
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis.
Loktionov A; Watson MA; Stebbings WS; Speakman CT; Bingham SA
Cancer Lett; 2003 Jan; 189(2):189-96. PubMed ID: 12490312
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphism of the plasminogen activator inhibitor-1 is associated with an increased risk of endometrial cancer.
Su CK; Yeh KT; Yeh CB; Wang PH; Ho ES; Chou MC; Liu KC; Yang SF; Yi YC
J Surg Oncol; 2011 Dec; 104(7):755-9. PubMed ID: 21761413
[TBL] [Abstract][Full Text] [Related]
6. Significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 (PAI-1) expression in human colorectal carcinomas.
Papadopoulou S; Scorilas A; Yotis J; Arnogianaki N; Plataniotis G; Agnanti N; Talieri M
Tumour Biol; 2002; 23(3):170-8. PubMed ID: 12218297
[TBL] [Abstract][Full Text] [Related]
7. The role of cysteine and serine proteases in colorectal carcinoma.
Herszènyi L; Plebani M; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
Cancer; 1999 Oct; 86(7):1135-42. PubMed ID: 10506696
[TBL] [Abstract][Full Text] [Related]
8. Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer.
Ganesh S; Sier CF; Heerding MM; van Krieken JH; Griffioen G; Welvaart K; van de Velde CJ; Verheijen JH; Lamers CB; Verspaget HW
Br J Cancer; 1997; 75(12):1793-801. PubMed ID: 9192984
[TBL] [Abstract][Full Text] [Related]
9. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
[TBL] [Abstract][Full Text] [Related]
10. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas.
Fujii T; Obara T; Tanno S; Ura H; Kohgo Y
Hepatogastroenterology; 1999; 46(28):2299-308. PubMed ID: 10521987
[TBL] [Abstract][Full Text] [Related]
11. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells.
Alvarez-Millán JJ; Bocos C; Ferrín V; Lucas AR; Ruibal A; Schneider J
Oncology; 2002; 62(3):286-90. PubMed ID: 12065877
[TBL] [Abstract][Full Text] [Related]
12. A C/T polymorphism in the urokinase-type plasminogen activator gene in colorectal cancer.
Przybylowska K; Smolarczyk K; Blasiak J; Kulig A; Romanowicz-Makowska H; Dziki A; Ulanska J; Pander B
J Exp Clin Cancer Res; 2001 Dec; 20(4):569-72. PubMed ID: 11876553
[TBL] [Abstract][Full Text] [Related]
13. Genetic polymorphism of urokinase-type plasminogen activator is interacting with plasminogen activator inhibitor-1 to raise risk of cervical neoplasia.
Tee YT; Wang PH; Tsai HT; Lin LY; Lin HT; Yang SF; Hsieh YH; Ying TH
J Surg Oncol; 2012 Aug; 106(2):204-8. PubMed ID: 22354580
[TBL] [Abstract][Full Text] [Related]
14. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor 1 (PAI-1) levels and gene promoter polymorphisms in subjects with colorectal cancer.
Smolarz B; Blasiak J; Kulig A; Romanowicz-Makowska H; Dziki A; Ulanska J; Pander B; Szewczyk T
J Exp Clin Cancer Res; 2001 Jun; 20(2):247-52. PubMed ID: 11484982
[TBL] [Abstract][Full Text] [Related]
16. Clinical impact of PAI 1 4G/5G gene polymorphism in colorectal carcinoma patients.
Halamkova J; Kiss I; Pavlovsky Z; Tomasek J; Jarkovsky J; Cech Z; Bednarova D; Tucek S; Hanakova L; Moulis M; Zavrelova J; Man M; Benda P; Robek O; Kala Z; Penka M
Neoplasma; 2013; 60(2):151-9. PubMed ID: 23259783
[TBL] [Abstract][Full Text] [Related]
17. [The role of cathepsins and the plasminogen activator/inhibitor system in colorectal cancer].
Herszényi L; Farinati F; Plebani M; István G; Sápi Z; Carraro P; De Paoli M; Naccarato R; Tulassay Z
Orv Hetil; 1999 Aug; 140(33):1833-6. PubMed ID: 10489782
[TBL] [Abstract][Full Text] [Related]
18. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
[TBL] [Abstract][Full Text] [Related]
19. The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.
Brungs D; Chen J; Aghmesheh M; Vine KL; Becker TM; Carolan MG; Ranson M
Oncotarget; 2017 Apr; 8(14):23099-23109. PubMed ID: 28416743
[TBL] [Abstract][Full Text] [Related]
20. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]